Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Ayers, E;Depaus, Julien;Offner, Fritz;Hu, Marie;Alderuccio, Juan Pablo;et.al.
(2024) Society of Hematologic Oncology Annual Meeting (SOHO 2024) — Location: Houston, TX, USA (4.September.2024)

Files

21017SOHO2024LOTIS-7TiPUpdateEncorePosterFinal.pdf
  • Open Access
  • Adobe PDF
  • 645.84 KB
Download

Details

Authors
  • Ayers, E
    Author
  • Depaus, JulienUCLouvain
    Author
  • Offner, Fritz
    Author
  • Hu, Marie
    Author
  • Alderuccio, Juan Pablo
    Author
Show more
Abstract
INTRODUCTION ● Lonca, an antibody–drug conjugate comprising a humanized anti-CD19 antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer cytotoxin, received accelerated approval by the United States Food and Drug Administration and has received conditional marketing authorization by the European Commission to treat adult patients with R/R diffuse large B-cell lymphoma (DLBCL) after ≥2 lines of systemic therapy1,2 – A phase 2 trial of Lonca monotherapy in patients with R/R DLBCL showed that an intravenous (IV) infusion over 30 minutes on day (D) 1 of each 3-week cycle produced durable responses with manageable toxicity using a dose of 150 μg/kg for 2 cycles and then 75 μg/kg for subsequent cycles3 ● Combining agents with different mechanisms of action may enhance treatment efficacy in patients with R/R B-NHL – In preclinical WSU-DLCL2 and Ramos xenograft models, Lonca in combination with polatuzumab vedotin (Pola) showed improved antitumor activity with better response rates compared with either monotherapy alone4 – In addition, combining CD20 × CD3 T-cell–engaging antibodies (eg, glofitamab [Glofit]5 or mosunetuzumab [Mosun]6) with Lonca is expected to increase antitumor activity
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Ayers, E., Depaus, J., Offner, F., Hu, M., Okada, C., Urban, A., Niewiarowski, A., Rave, E., Laughlin, M., & Alderuccio, J. P. (2024). Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7). Society of Hematologic Oncology Annual Meeting (SOHO 2024), Houston, TX, USA. https://hdl.handle.net/2078.5/274817